Page 17 - Read Online

Skopis et al. Vessel Plus 2020;4:30 I http://dx.doi.org/10.20517/2574-1209.2020.42 Page 13 of 14

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception and design of this review and performed data interpretation:
Skopis M, Bag-Ozbek A

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond) 2017;17:60-4.
2. Jennette JC, Nachman PH. ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol 2017;12:1680-91.
3. Fauci AS, Wolff SM. Wegner’s Granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore)
1973;52:535-61.
4. Hassan RI, Gaffo AL. Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep 2017;19:6.
5. de Groot K, Harper L, Jayne D, Felipe L, Gregorini G et al. Pulse versus oral cyclophosphamide for induction of remission in
antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
6. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, et al. Randomized trial of cyclophosphamide versus methotrexate for
induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
7. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, et al; European Vasculitis Study Group. Randomized trial of plasma
exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
8. Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, et al; PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe
ANCA-associated vasculitis. N Engl J Med 2020;382:622-31.
9. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-
associated vasculitis. N Engl J Med 2010;363:221-32.
10. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide
in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
11. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, et al; European Vasculitis Study Group. A randomized trial of maintenance
therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
12. Maritati F, Alberici F, Oliva E, Urban ML, Palmisano A, et al. Methotrexate versus cyclophosphamide for remission maintenance in
ANCA-associated vasculitis: a randomised trial. PLoS One 2017;12:e0185880.
13. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance
for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
14. Randall KL. Rituximab in autoimmune diseases. Aust Prescr 2016;39:131-4.
15. Jennette JC, Falk RJ. B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 2014;36:327-38.
16. Specks U, Fervenza FC, Mcdonald TJ, Hogan MCE. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody
therapy. Arthritis Rheum 2001;44:2836-40.
17. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med
2005;257:540-8.
18. Bruhaye B, Aouba A, Pagnoux C, Lacassin F, Guillevin L. Adjunction of Rituximab to steroids and immunosuppressants for refractory/